Tau levels fall, cognitive decline slows with diranersen
Patients with early Alzheimer’s disease treated with diranersen experienced slower cognitive decline and greater reductions in tau compared with placebo, according to data presented at the Alzheimer’s Association International Conference.
Diranersen (BIIB080, Biogen) is an investigational antisense oligonucleotide therapy that reduces tau production by targeting microtubule-associated protein tau mRNA, including intracellular and extracellular tau, unlike other therapies that only reduce extracellular tau, Biogen said in a press release.
“Addressing intracellular tau is particularly important